Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?

Francia P, Palano F, Tocci G, Adduci C, Ricotta A, Semprini L, Caprinozzi M, Balla C, Volpe M.

ISRN Cardiol. 2014 Feb 6;2014:652421. doi: 10.1155/2014/652421. eCollection 2014. Review.

2.

Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.

Makkar KM, Sanoski CA, Spinler SA.

Pharmacotherapy. 2009 Jan;29(1):31-48. doi: 10.1592/phco.29.1.31. Review.

PMID:
19113795
3.

Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(13):1-60. Epub 2005 Sep 1.

4.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.

5.

Angiotensin II type 1 receptor blockade: high hopes sent back to reality?

Grothusen A, Divchev D, Luchtefeld M, Schieffer B.

Minerva Cardioangiol. 2009 Dec;57(6):773-85. Review.

PMID:
19942847
6.
7.
8.

ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.

PMID:
16259523
9.

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators.

Am J Cardiovasc Drugs. 2007;7(5):373-80.

PMID:
18041162
10.

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.

Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H.

Am J Kidney Dis. 2016 May;67(5):728-41. doi: 10.1053/j.ajkd.2015.10.011. Epub 2015 Nov 18.

PMID:
26597926
11.

ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.

Schindler C.

Ther Adv Cardiovasc Dis. 2008 Aug;2(4):233-48. doi: 10.1177/1753944708094309.

PMID:
19124424
12.
13.

Exploring new treatment strategies in heart failure.

Swedberg K.

Blood Press Suppl. 2000;1:44-8. Review.

PMID:
11059637
14.
16.

Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis.

Mantziari L, Guha K, Khalique Z, McDonagh T, Sharma R.

Am J Cardiol. 2012 Jun 1;109(11):1619-25. doi: 10.1016/j.amjcard.2012.01.387. Epub 2012 Mar 31.

PMID:
22465318
17.
18.

Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy?

E Gullo C, de Almeida Zia VA, Vilela-Martin JF.

Recent Pat Cardiovasc Drug Discov. 2014;9(1):28-37. Review.

PMID:
24993597
19.

Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.

Lelakowski J, Piekarz J, Rydlewska A, Majewski J, Senderek T, Ząbek A, Małecka B.

Kardiol Pol. 2012;70(11):1099-110.

20.

Angiotensin receptor blockers: evidence for preserving target organs.

Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Siragy HM.

Clin Cardiol. 2001 Mar;24(3):183-90.

Supplemental Content

Support Center